118 related articles for article (PubMed ID: 7795140)
21. Financial aspects of haemophilia care in Puerto Rico and other Latin American countries.
Santiago-Borrero PJ; Ortiz I; Rivera-Caragol E; Maldonado NI
Haemophilia; 1999 Nov; 5(6):386-91. PubMed ID: 10583524
[TBL] [Abstract][Full Text] [Related]
22. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
[TBL] [Abstract][Full Text] [Related]
23. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand.
Unim B; Veneziano MA; Boccia A; Ricciardi W; La Torre G
ScientificWorldJournal; 2015; 2015():596164. PubMed ID: 25685844
[TBL] [Abstract][Full Text] [Related]
24. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
26. Can the supply and demand for plasma-derived products ever be reconciled? Self-sufficiency from the viewpoint of a blood transfusion service.
Leikola J
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S15-7. PubMed ID: 7795132
[TBL] [Abstract][Full Text] [Related]
27. Economic costs of hemophilia and the impact of prophylactic treatment on patient management.
Chen SL
Am J Manag Care; 2016 Apr; 22(5 Suppl):s126-33. PubMed ID: 27266809
[TBL] [Abstract][Full Text] [Related]
28. Haemophilia and home therapy.
Lancet; 1979 Jul; 2(8133):77-8. PubMed ID: 87970
[No Abstract] [Full Text] [Related]
29. Haemophilia care in Europe: the ESCHQoL study.
Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit.
Roosendaal G; Lafeber F
N Engl J Med; 2007 Aug; 357(6):603-5. PubMed ID: 17687136
[No Abstract] [Full Text] [Related]
31. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.
Lorenzoni V; Triulzi I; Turchetti G
BMC Health Serv Res; 2018 Aug; 18(1):596. PubMed ID: 30071878
[TBL] [Abstract][Full Text] [Related]
32. Practice patterns in haemophilia A therapy -- global progress towards optimal care.
Geraghty S; Dunkley T; Harrington C; Lindvall K; Maahs J; Sek J
Haemophilia; 2006 Jan; 12(1):75-81. PubMed ID: 16409179
[TBL] [Abstract][Full Text] [Related]
33. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
Ullman M; Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
[TBL] [Abstract][Full Text] [Related]
34. Healthcare resource utilization among haemophilia A patients in the United States.
Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
[TBL] [Abstract][Full Text] [Related]
35. Financing the rising cost of haemophilia care at a large comprehensive care centre.
Miners AH; Sabin CA; Stevens AJ; Tolley KH; Lee CA
J R Coll Physicians Lond; 1997; 31(6):640-4. PubMed ID: 9409497
[TBL] [Abstract][Full Text] [Related]
36. Haemophilia treatment in the United Kingdom from 1969 to 1974.
Biggs R
Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406
[TBL] [Abstract][Full Text] [Related]
37. Hemophilia replacement therapy in developing countries: complementary approaches to the question of indigenous product manufacture versus importation.
Gellert GA
Thromb Haemost; 1996 Feb; 75(2):373-4. PubMed ID: 8815594
[No Abstract] [Full Text] [Related]
38. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
39. Cost of severe haemophilia in Toronto.
Heemstra HE; Zwaan T; Hemels M; Feldman BM; Blanchette V; Kern M; Einarson TR
Haemophilia; 2005 May; 11(3):254-60. PubMed ID: 15876271
[TBL] [Abstract][Full Text] [Related]
40. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
